Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $580,909.78 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Karen M. Anderson sold 30,526 shares of Centessa Pharmaceuticals stock in a transaction on Friday, February 7th. The shares were sold at an average price of $19.03, for a total transaction of $580,909.78. Following the completion of the sale, the insider now owns 54,322 shares in the company, valued at approximately $1,033,747.66. This represents a 35.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Centessa Pharmaceuticals Stock Up 4.3 %

Shares of NASDAQ:CNTA opened at $18.00 on Thursday. The company has a market cap of $2.37 billion, a price-to-earnings ratio of -11.76 and a beta of 1.53. Centessa Pharmaceuticals plc has a 12 month low of $7.75 and a 12 month high of $19.09. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a 50-day moving average price of $16.80 and a 200 day moving average price of $15.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.05. As a group, equities research analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. boosted its stake in Centessa Pharmaceuticals by 47.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after buying an additional 826 shares during the period. GAMMA Investing LLC boosted its stake in shares of Centessa Pharmaceuticals by 103.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after purchasing an additional 1,509 shares during the period. Walleye Capital LLC bought a new position in Centessa Pharmaceuticals during the 3rd quarter valued at about $187,000. China Universal Asset Management Co. Ltd. raised its position in Centessa Pharmaceuticals by 99.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock worth $217,000 after purchasing an additional 6,785 shares during the period. Finally, Harbour Capital Advisors LLC bought a new stake in Centessa Pharmaceuticals in the third quarter worth about $259,000. Institutional investors own 82.01% of the company’s stock.

Wall Street Analysts Forecast Growth

CNTA has been the topic of several research reports. Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday. TD Cowen assumed coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating on the stock. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.